MarketCapExport financials
10x Genomics (TXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
10x Genomics Balance Sheet 2025-2011 | TXG
Brief overview of 10x Genomics's financial position
This overview follows the five latest available annual observations between 2021 and 2025.
Assets changed little, standing at $1 billion initially and $1 billion at the end. The balance sheet stayed close to its former scale.
Liabilities expanded faster than the asset base, +21.8% versus +2.2%. Debt-service capacity deserves attention.
Equity accounts for 76.5% of assets. Against the initial 80.2%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$389.6 million. The balance sheet therefore carries a net cash position.
Cash accounts for 45.5% of assets versus 57.7% initially. The change indicates the degree of financial flexibility.
Retained earnings are negative at -$1.5 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Conclusion
10x Genomics's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet 10x Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-390 M | -261 M | -264 M | -125 M | -505 M | -601 M | -394 M | -35.4 M | -37.3 M | - | - | - | - | - | - |
Long Term Debt |
73.4 M | 73.3 M | 83.8 M | 86.1 M | 76.8 M | 57 M | 19.8 M | 25.5 M | 6.34 M | - | - | - | - | - | - |
Long Term Debt Current |
11 M | 9.29 M | 11.5 M | 9.04 M | 5.13 M | 5.94 M | 9.88 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 123 M | 312 M | 166 M | - | - | - | - | - | - |
Total Current Liabilities |
153 M | 118 M | 127 M | 131 M | 110 M | 118 M | 63 M | - | - | - | - | - | - | - | - |
Total Liabilities |
245 M | 209 M | 224 M | 223 M | 201 M | 190 M | 186 M | 344 M | 188 M | - | - | - | - | - | - |
Deferred Revenue |
23.9 M | 20.7 M | 13.2 M | 7.87 M | 5.34 M | 4.47 M | 4.6 M | 2.78 M | 1.83 M | - | - | - | - | - | - |
Retained Earnings |
-1.51 B | -1.47 B | -1.28 B | -1.03 B | -863 M | - | -262 M | -231 M | -119 M | - | - | - | - | - | - |
Total Assets |
1.04 B | 919 M | 965 M | 1.03 B | 1.02 B | 929 M | 606 M | 124 M | 75.6 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
474 M | 344 M | 359 M | 220 M | 587 M | 664 M | 424 M | 65.1 M | 47.9 M | - | - | - | - | - | - |
Book Value |
796 M | 710 M | 741 M | 806 M | 818 M | 739 M | 420 M | -220 M | -113 M | - | - | - | - | - | - |
Total Shareholders Equity |
796 M | 710 M | 741 M | 806 M | 818 M | 739 M | 420 M | -220 M | -113 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet 10x Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
70.1 M | 76.4 M | 77.1 M | 70.6 M | 76.5 M | 78.7 M | 81 M | - | - | 92.8 M | 86.1 M | - | 91 M | 93.5 M | 76.8 M | 75.7 M | 65.9 M | 66.3 M | - | - | - | - | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 25.5 M | 25.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
201 M | 242 M | 207 M | 196 M | 215 M | 206 M | 204 M | - | - | 212 M | 223 M | - | 218 M | 197 M | 201 M | 190 M | 193 M | 202 M | 190 M | 190 M | 190 M | 190 M | 186 M | 186 M | 186 M | 186 M | 101 M | 101 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
24.3 M | 22.1 M | 21.4 M | 20.9 M | 17.8 M | 16.4 M | 14.3 M | - | - | 8.53 M | 7.87 M | - | 6.47 M | 5.43 M | 5.34 M | 5.5 M | 5.27 M | 4.48 M | 4.47 M | 4.47 M | 4.47 M | 4.47 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 2.4 M | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.52 B | -1.49 B | -1.47 B | -1.5 B | -1.42 B | -1.38 B | -1.34 B | - | - | -1.08 B | -1.03 B | - | -970 M | -906 M | -863 M | -845 M | -828 M | -817 M | -805 M | -805 M | -805 M | -805 M | -262 M | -262 M | -262 M | -262 M | -231 M | -231 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.02 B | 1.03 B | 980 M | 903 M | 938 M | 930 M | 923 M | - | - | 1.01 B | 1.03 B | - | 1 B | 1 B | 1.02 B | 991 M | 978 M | 954 M | 929 M | 929 M | 929 M | 929 M | 606 M | 606 M | 606 M | 606 M | 124 M | 124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
490 M | 433 M | 398 M | 377 M | 398 M | 380 M | 356 M | 315 M | 331 M | 340 M | 227 M | - | 282 M | 320 M | 596 M | 609 M | 649 M | 644 M | 689 M | 689 M | 689 M | 689 M | 424 M | 427 M | 476 M | 476 M | 65.1 M | 65.1 M | - | - | 47.9 M | - | - | - | 41.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
814 M | 785 M | 773 M | 707 M | 723 M | 724 M | 719 M | - | - | 802 M | 806 M | - | 784 M | 807 M | 818 M | 800 M | 785 M | 752 M | 739 M | 739 M | 739 M | 739 M | 420 M | 420 M | 420 M | 420 M | 23.3 M | 23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
814 M | 785 M | 773 M | 707 M | 723 M | 724 M | 719 M | 745 M | 793 M | 802 M | 806 M | - | 784 M | 807 M | 818 M | 800 M | 785 M | 752 M | 739 M | 739 M | 739 M | 739 M | 420 M | 420 M | 420 M | 420 M | -220 M | -220 M | -132 M | -127 M | -113 M | - | - | - | -96.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of 10x Genomics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |